Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
about
Genetics and Therapeutics in Pediatric Ulcerative Colitis: the Past, Present and FutureCurrent stage in inflammatory bowel disease: What is next?Medical Therapy of Active Ulcerative ColitisScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesHistologic scoring indices for evaluation of disease activity in ulcerative colitis.CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.CXCL13 antibody for the treatment of autoimmune disorders.Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.Leukocyte Trafficking to the Small Intestine and ColonQingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response.Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.New therapies for primary biliary cirrhosis.Targeting leukocyte trafficking for the treatment of inflammatory bowel disease.Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.Review article: the histological assessment of disease activity in ulcerative colitis.Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developmentsEmerging therapeutic targets and strategies in Crohn's disease.Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon CellsNovel Therapies for Thyroid Autoimmune Diseases.Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.Genetic risk variants as therapeutic targets for Crohn's disease.Emerging treatments for ulcerative colitis: a systematic review.NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8+ T cell migrationAnti-NKG2D mAb: A New Treatment for Crohn's Disease?Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes.Novel treatment options for ulcerative colitis.Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17Noncanonical Effects of IRF9 in Intestinal Inflammation: More than Type I and Type III Interferons.Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.T Follicular Helper Cells As a New Target for Immunosuppressive Therapies.Immunoaffinity LC-MS/MS for quantitative determination of a free and total protein target as a target engagement biomarker.Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.A functional genomics predictive network model identifies regulators of inflammatory bowel disease.Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES.Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid.
P2860
Q26765893-A326AAA0-401C-4DCE-A0E0-3AF179841965Q26777429-5C7758D0-ECCE-47E7-8E61-3127190411E2Q26777729-611C0CB3-A1FD-4DF0-B0F3-5EA6ADB9287DQ26798209-18BE4A85-A0C3-4B57-946C-6E233B506D18Q30234366-4779B1AD-4DC8-40D2-B1BF-C4460A866133Q33864128-10DA56C1-45C0-4C89-A0FC-7C4050C4DFD9Q34507117-988726FE-53DB-462F-B605-326530A03BE7Q35086918-28C4EBE4-0E14-481B-A273-56BAE4101EE8Q35889006-6B4A5BA4-DCDC-4AE6-AAE4-E8711EC96629Q36592984-C601067F-ABCE-4059-B8AA-F920AEE17B0DQ37054120-983A9501-6783-4B81-AD36-C0489789241CQ37546954-11E55560-87AF-46B0-98C3-2840221A4FECQ38261577-86AEC816-87ED-48FC-B559-D055C6713E42Q38351464-C17C936B-0DF4-40B1-B052-6C6CCBAFA66AQ38379118-541CD06F-04A5-4FE0-A9E5-7CB652478963Q38573248-78D94F3D-FC51-4090-95D8-AB89C141BB42Q38591688-45778A86-725D-4FD9-A3CA-073194FBB115Q38696392-5707FB46-9AD2-411D-9B72-BA8161A5DEF3Q38731835-4786F036-1525-4EF6-93A1-D93E5D8C49FAQ38743624-2EE3CA27-02C6-49EA-B7C8-44C7B5F8D93BQ38744708-D1CDB550-EB9B-46B6-BBBF-39BFBE6BB4D5Q38915139-CC9CDDF3-778C-463F-B0FD-A6A39633690AQ39306383-D66D20DC-730F-4180-8932-C902B587486AQ41442867-2C2BE373-FA33-4A91-9481-B260FC79E607Q41660377-36FC3AB1-0BA2-469C-907D-43BC9CE02EBDQ41678385-E2CD1792-4E5C-4292-9E4E-DDC7A2569B09Q41904871-30D0E0F9-B5E0-42CF-B535-93FA651E712EQ41949151-65F29D03-2977-4637-9A04-664A44C174F6Q41990117-0D87D011-A250-4A4C-933C-BBF03D971F14Q42710048-FB5DBB66-C1C3-4448-9135-76C3BE688674Q43116514-0BC36CE0-B128-48CF-8B7A-FCDA247A0DD5Q47109235-C8C4D08F-2D3F-4896-A5DC-51CC9BA8C9B5Q47601399-E90D1C48-E80A-46F6-A331-146DF3171536Q47958039-9CE0343B-1072-4865-BC80-F6D976417B30Q48004039-5F50C0CF-2465-4D54-AC45-84085AE03924Q48847115-3555CAD8-9030-459D-B114-B08A828BBD46Q49790075-67964EEB-65E9-4AE3-9EF3-D04C67EB83F6Q50205262-59EF7948-58CF-43A5-A4D8-8B4591F5A5F3Q55052878-521911D8-F61B-4926-82D3-B3AA84A31570Q55202763-B5F358E6-50E7-440B-B48D-32C8392062A1
P2860
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
@en
Anti-IP-10 antibody
@nl
type
label
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
@en
Anti-IP-10 antibody
@nl
prefLabel
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
@en
Anti-IP-10 antibody
@nl
P2093
P2860
P1433
P1476
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
@en
P2093
Allison Y Luo
Karel Geboes
Lloyd Mayer
Luisa Salter-Cid
Michael Yellin
Richard Aranda
Robert Hardi
Sheila Gujrathi
Xiaolu Tao
P2860
P304
P356
10.1136/GUTJNL-2012-303424
P407
P577
2013-03-05T00:00:00Z